ESSENTIALS FOR PATIENTS
Patient resources and information
The thought of hair loss and nerve damage during chemotherapy can be scary and we know there’s already a lot to process. This page provides all the essential patient information before treatment starts.
Reduce hair loss
Reduce nerve damage
Join our community
Find a Paxman System near you
Scalp cooling outcomes calculator
Estimates are averaged percentages based on Scalp Cooling Registry data of over 7,000 real-world patients. Regimens and dosages included are those that have exceeded a minimum sample size threshold (n=10) to offer an interpretation of efficacy. Depending on sample size, results may show greater variation. There are no guarantees, but an indication of potential outcome will help to manage expectations. Pre-infusion and post-infusion cooling times per regimen are also displayed.
Start
Select your regimen
- Cabazitaxel (Jevtana) 25-50
- Cabazitaxel (Jevtana) 35-55
- Carboplatin 6 + Etoposide 50
- Cisplatin 25-75
- Cyclophosphamide 100 + Methotrexate 40 + 5-FU 600
- Cyclophosphamide 600 + Methotrexate 40 + 5-FU 600
- Docetaxel (Taxotere) 35
- Docetaxel (Taxotere) 75
- Docetaxel (Taxotere) 80
- Docetaxel (Taxotere) 100
- Docetaxel (Taxotere) 100H
- Doxorubicin (Adriamycine) 25
- Doxorubicin (Adriamycine) 60
- Epirubicin 25-90
- Epirubicin 50 + Oxaliplatin 130
- Eribulin
- Irinotecan (Campto) 180-250
- Irinotecan (Campto) 260-340
- Irinotecan (Campto) 350
- Methotrexate 10-30
- Mitomycin 60
- Mitomycin 60 + Cyclophosphamide 600
- Paclitaxel (Taxol) 50-75
- Paclitaxel (Taxol) 80
- Paclitaxel (Taxol) 80 + Trastuzumab
- Paclitaxel (Taxol) 90
- Paclitaxel (Taxol) 175
- Pegylated liposomal Doxorubicin 30-50
- Pegylated liposomal Doxorubicin + Carboplatin 5
- Pemetrexed 500
- Vinorelbine (Navelbine) 25
- Vinorelbine (Navelbine) 30
- AC: doxorubicin 60 + cyclophosphamide 600
- AC-D: doxorubicin 60 + cyclophosphamide 600 followed by docetaxel 100
- AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 80
- AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 80 + Trastuzumab
- AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 175
- AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 175 + Trastuzumab
- Docetaxel 75 + carboplatin 5-6
- Docetaxel + Pemetrexed
- Docetaxel 75 + cyclophosphamide 600
- FAC: fluorouracil (5-FU) 500 + doxorubicin 50 + cyclophosphamide 500
- FAC: fluorouracil (5-FU) 500 + doxorubicin 60 + cyclophosphamide 500
- FEC: fluorouracil (5-FU) 500 + epirubicin 50-70 + cyclophosphamide 500
- FEC: fluorouracil (5-FU) 500 + epirubicin 75-85 + cyclophosphamide 500
- FEC: fluorouracil (5-FU) 500 + epirubicin 90 + cyclophosphamide 500
- FEC: fluorouracil (5-FU) 500 + epirubicin 100 + cyclophosphamide 500
- FEC-D: fluorouracil (5-FU) 500 + epirubicin 90 + cyclophosphamide 500 followed by docetaxel 100
- FEC-D: fluorouracil (5-FU) 500 + epirubicin 100 + cyclophosphamide 500 followed by docetaxel 100
- FEC-T: fluorouracil (5-FU) 500 + epirubicin 100 + cyclophosphamide 500 followed by paclitaxel 80-100
- Gemcitabine 1000
- Gemcitabine 1000-1250 + carboplatin 4-6
- Paclitaxel 50 + carboplatin 2
- Paclitaxel 80 + carboplatin 2
- Paclitaxel 80 + carboplatin 5-6
- Paclitaxel 175 + carboplatin 5-6
- Paclitaxel 70 + carboplatin 3
- Paclitaxel 80 + avastin 10-15 mg/kg
- Paclitaxel 90 + avastin 10-15 mg/kg
- TAC: docetaxel 75 + doxorubicin 50 + cyclophosphamide 500
Outcome results
Your selected drug regimen:
Your outcome results:
Pre-infusion cooling time
Post-infusion cooling time:
Our most frequently asked questions;
Can cryocompression treatment for CIPN prevent all peripheral nerve damage?
Patients cannot be guaranteed that they will not develop neuropathy. However, in a clinical trial of 150 patients, the Paxman Neuropathy was shown to be effective in reducing the relative risk of incidence of any grade of CIPN in 70% of patients. Fewer than 2% of patients in the trial developed CTCAE Grade 2 CIPN or above. Grade 2 reflects symptoms that interfere with instrumental activities of daily living and may influence treatment decisions.
Will neuropathy be completely prevented or treated?
The Paxman Neuropathy is intended to reduce the likelihood and severity of nerve damage symptoms. Although success cannot be guaranteed, clinical trials have shown a significant reduction in the number of patients experiencing symptoms or in the severity of their symptoms.
Will using the Paxman Neuropathy System impact how well my chemotherapy works?
No. The Paxman Neuropathy System does not change how chemotherapy treats your cancer.
What is scalp cooling?
Scalp cooling has long been the only scientifically validated method of reducing chemotherapy hair loss and promoting quicker hair regrowth post treatment.
Can scalp cooling prevent all hair loss?
Scalp cooling cannot guarantee complete hair preservation.
Efficacy varies based on a series of factors, with the chemotherapy drug regimens being the primary influence. Taxane based regimens see the highest rates of hair retention, and although anthracycline regimens see a lower level of efficacy, scalp cooling with anthracyclines is still beneficial. As a safe and tolerable treatment, it is also proven to support regrowth, prevention of permanent chemotherapy-induced alopecia (PCIA) and improving quality of life. Most patients experience some degree of shedding or thinning. However, many patients retain enough hair that they do not feel the need to wear a wig or head covering.
What should patients expect during treatment?
Patients wear a Paxman Scalp Cooling Cap before, during, and after chemotherapy. The first 1015 minutes are often described as the coldest, after which most patients become accustomed to the sensation. Treatment times vary depending on the chemotherapy regimen.
For any further questions, visit our FAQs page
Patient Scalp Cooling resources:
Patient Neuropathy resources:
